ArticleCancer chemotherapy and pharmacology2012

Phase I study of the Aurora B kinase inhibitor barasertib (AZD1152) to assess the pharmacokinetics, metabolism and excretion in patients with acute myeloid leukemia.

Mike Dennis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.